Among clinicians the topic of quality-of-life assessment inspires a range of emotions, the most prevalent of which is scepticism. The matter has been discussed lately in the JRSM by Wulff and by Koller and Lorenz. However, in clinical trials it is vital that we include the patient's perspective as well as the easily measured clinical indices. Therefore we must make the best possible use of existing tools, so that the cries of the sceptics are at least hushed. A major reason for the mistrust of quality-of-life assessment is that too often this aspect of research has been poorly applied, with inappropriate instruments tagged on to a trial as a mere gesture.
Quality of Life, a short publication from BMJ Books, may well live up to the claim on its cover of being 'invaluable for all researchers and clinicians wanting to improve delivery of care to patients with chronic disease'. It is a concise overview of the 'state of the science', presented in a style accessible to those who lack a specialist interest in the subject. Perhaps the most important of the hot topics is 'response shift', the theory that changes in quality of life in patients with chronic conditions result at least in part from adaptation to the situation in which the patient finds him/ herself. Response shift has only lately received attention but has enormous implications for the assessment of quality of life, particularly in the interpretation of change and in shedding light on the paradoxical findings so often obtained.
Another key issue is how to select a suitable quality-of-life instrument. Ann Bowling, in her opening chapter, indicates that the use of inappropriate scales is commonly due to a failure to clarify the concept of quality of life. Subsequent chapters address the difficulties inherent in selection of instruments and provide practical guidance such as 'Ten steps for assessing and choosing a quality of life measure for clinical practice'. Attention is also paid to the special issues in groups such as children and caregivers, with practical guidance for conducting trials in these populations.
The science of quality-of-life assessment is still in its infancy. Allison Carr and her co-editors have provided an excellent brief account of the state of play, and I recommend it to all who design or interpret clinical trials. The revised and updated second edition of An Introduction to Vascular Biology is broader in scope than its predecessor and more clinically oriented. The extent to which vascular biology and pathophysiology impacts upon clinical medicine is perfectly illustrated by the varied departmental affiliations of the four editors-haematology, rheumatology, obstetrics and vascular surgery. The book includes nineteen short, digestible chapters grouped under basic science, pathophysiology and clinical practice. Contributors include respected names such as Peter Weissberg, Patrick Vallance, Caroline Savage, Allun Hughes and John Tooke. Each chapter has a list of useful up-to-date references, but the illustrations would have benefited from a splash of colour (especially the clinical photographs and histological sections).
The basic science section is comprehensive, with useful introductory chapters on topical subjects such as angiogenesis, vascular cell apoptosis, and the biology of wound healing. The whole area of angiogenesis is particularly relevant clinically. Sprouting of new blood vessels from existing vascular structures plays an important part in collateral vessel formation, tumour growth and tissue remodelling and regeneration. This chapter describes the regulation of endothelial cell migration and proliferation, with connective tissue expansion and the gradual creation of new vascular architecture. Numerous growth factors stimulate angiogenesis while other anti-angiogenic molecules inhibit new vessel formation. The basic science is outlined in a clinical context with reference to conditions in which therapeutic manipulation of angiogenic pathways has potential benefits. This might be achieved, for example, by gene therapy whereby DNA for a powerful angiogenic growth factor, VEGF, is administered locally in the leg or the heart to enhance new vessel formation in patients with critical ischaemia. Conversely, there is a rationale for inhibition of angiogenesis as a way to block tumour growth in primary or metastatic disease. The chapter on 
